Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering
01:55am, Wednesday, 22'nd Jul 2020
HAMILTON, Bermuda, July 21, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 5,952,3
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
08:07pm, Monday, 20'th Jul 2020
HAMILTON, Bermuda, July 20, 2020 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of $100.0.
Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis
11:30am, Thursday, 16'th Jul 2020
HAMILTON, Bermuda, July 16, 2020 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and.
J.P. Morgan Says These 3 Stocks Will Surge Over 30% From Current Levels
04:53pm, Wednesday, 08'th Jul 2020
Amid the recent surge of new COVID-19 cases, do stocks still have more room to climb? J.P. Morgan says yes. According to strategist Marko Kolanovic, who correctly called stocks’ March bottom, there
Hedge Funds Are Betting On Kiniksa Pharmaceuticals, Ltd. (KNSA)
03:03am, Monday, 06'th Jul 2020
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that sm
Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group
Company News for Jun 30, 2020
01:35pm, Tuesday, 30'th Jun 2020
Companies in the news are: KNSA, TLSA, COTY, ICPT
Kiniksa's Heart Drug, And Other News: The Good, Bad, And Ugly Of Biopharma
01:14pm, Tuesday, 30'th Jun 2020
Kiniksa's heart inflammation drug shows positive results. Heron's HTX-011 gets a CRL. SEGN's Tisotumab Vedotin reports positive data.
3 “Strong Buy” Coronavirus Stocks With Massive Upside Potential
07:47pm, Monday, 29'th Jun 2020
COVID-19 might not be going anywhere anytime soon. Last week, Florida, Texas, California and Arizona all reported that the daily rate of new infections had spiked. Heightened fears of a second wave an
Kiniksa Reports Positive Results of Pericarditis-Drug Trial
02:48pm, Monday, 29'th Jun 2020
Kiniksa shares rose after the biotech reported positive results from a Phase III trial of rilonacept to treat the autoinflammatory disease pericarditis.
5 Stocks With Recent Price Strength Amid Spike in Coronavirus
12:09pm, Monday, 29'th Jun 2020
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
11:15am, Monday, 29'th Jun 2020
RHAPSODY met its prespecified primary and all major secondary efficacy endpoints, showing that rilonacept improved clinically meaningful outcomes associated with the unmet medical need in recurrent pe
Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19
12:00pm, Wednesday, 17'th Jun 2020
The 28-day clinical outcomes data from the open-label treatment protocol with mavrilimumab are described in a manuscript by De Luca et al1 entitled, “GM-CSF Blockade with Mavrilimumab in Severe COV
Zacks.com featured highlights include: SunOpta, eXp World, Calix, Kiniksa Pharmaceuticals and iClick Interactive Asia Group
02:43pm, Friday, 12'th Jun 2020
Zacks.com featured highlights include: SunOpta, eXp World, Calix, Kiniksa Pharmaceuticals and iClick Interactive Asia Group
Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
12:00pm, Wednesday, 10'th Jun 2020
Additionally, the company expects mavrilimumab (anti-GM-CSFRα) Phase 2 data in giant cell arteritis (GCA) and KPL-404 (anti-CD40) single-ascending-dose Phase 1 data in the fourth quarter of 2020. �
